UCPVax
- Generic Name
- UCPVax
- Drug Type
- Biotech
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived from Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 105
- Registration Number
- NCT05528952
- Locations
- 🇫🇷
CH William Morey, Chalon-sur-Saône, France
🇫🇷CH de Mulhouse, Mulhouse, France
🇫🇷CHU de Besançon, Besançon, France
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 67
- Registration Number
- NCT04280848
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷CHU Besançon, Besançon, France
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: standard chemotherapy
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 60
- Registration Number
- NCT04263051
- Locations
- 🇫🇷
CHU de Nîmes, Nîmes, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷CHU Bordeaux, Bordeaux, France
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
Phase 2
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and NeckAnal Canal CancerCervical Cancer
- Interventions
- Biological: Blood sample collectionProcedure: Tumor biopsiesOther: CT scan
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 47
- Registration Number
- NCT03946358
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷CHU de Besançon, Besançon, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Universal Cancer Peptide-based Vaccination in Metastatic NSCLC
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 82
- Registration Number
- NCT02818426
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Besançon, Besancon, France
🇫🇷Hôpitaux Universitaires de Strasbourg, Strasbourg, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath